The WEGOVY market has experienced significant growth, driven by rising obesity rates and increasing demand for effective weight-loss treatments. Novo Nordisk's blockbuster drug has seen strong ...

New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...

It’s normal to have lots of questions when you start a new prescription medication. Whether you can drink alcohol might be at ...

Imagine a future where the grip of cocaine use disorder can be loosened, where cravings fade, and the risk of relapse diminishes.

For older adults with type 2 diabetes, use of GLP-1 RAs is associated with a modestly lower risk for depression compared with DPP-4i use.

Use of GLP-1 receptor agonists to treat type 2 diabetes is not associated with an increased risk of suicidality compared with ...

RAs are transforming obesity treatment, demonstrating substantial weight loss and metabolic improvements with lifestyle ...

While one study found lower rates of preterm birth alongside higher rates of hypertensive disorders, another found fewer ...

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic ...

The use of glucagon-like peptide-1 receptor agonists , such as semaglutide—marketed under brand names like Wegovy and Ozempic—has surged among adolescents and young adults. Between 2020 and 2023, the ...

A new study adds on to the growing evidence of potential mental health benefits of GLP-1RAs, along with other benefits it ...

Evidence suggests no increased risk The use of glucagon-like peptide-1 (GLP-1) receptor agonists has surged in recent years, driven by their benefits in glucose control in type 2 diabetes, weight ...